Stock FAE FAES FARMA, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Faes Farma, S.A.

Equities

FAE

ES0134950F36

Market Closed - BME
Other stock markets
 16:35:09 21/06/2024 BST 		5-day change 1st Jan Change
3.65 EUR -0.82% Intraday chart for Faes Farma, S.A. -2.28% +15.51%
05-23 FAES FARMA : Faes Farma is now receiving the long-awaited attention from investors Alphavalue
04-26 FAES FARMA : Q1 beat; full-year guidance re-affirmed Alphavalue

Evolution of the average Target Price on Faes Farma, S.A.

Price target over the last 5 years

History of analyst recommendation changes

84593dee61cb56a373f40.dCUMkso1hvrW_4fkeO1KazSN7ZDAlf-sBGyCf35xWYs.DnVJ4ItP8Y7vmfKyMr8-L3rUm8SrxJrmQTTnETVAHOEjRFvx-U_NiLyNyg~ec79a86dd41cceb55bc7b4b9684fac0e

Analyst Recommendations on Faes Farma, S.A.

FAES FARMA : Faes Farma is now receiving the long-awaited attention from investors Alphavalue
FAES FARMA : Q1 beat; full-year guidance re-affirmed Alphavalue
FAES FARMA : Q4 profitability exceeded expectations Alphavalue
FAES FARMA : Mixed Q3; markets need more from Faes to be convinced Alphavalue
FAES FARMA : A soft Q2, as expected; guidance maintained Alphavalue
FAES FARMA : Increased R&D focus and inflationary pressures to hold back near-to-medium term earnings Alphavalue
FAES FARMA : A healthy start to 2023 Alphavalue
FAES FARMA : 2022 guidance met + positive view maintained Alphavalue
Roche’s Alzheimer’s failure has sector-wide implications Alphavalue
FAES FARMA : Soft Q3, but 2022 guidance maintained Alphavalue
FAES FARMA : Another stronger quarter but maintained full-year outlook Alphavalue
FAES FARMA : Strong Q1; but some moderation lies ahead Alphavalue
FAES FARMA : A strong Q4 sums up a decent 2021 Alphavalue
FAES FARMA : An overall strong Q3 Alphavalue
FAES FARMA : Base business recovers in Q2; FY21 outlook reiterated despite resurfacing COVID-19 concerns Alphavalue
TODAY'S ANALYST RECOMMENDATIONS : Cisco, easyJet, L Brands, Mattel, Salesforce... Our Logo
FAES FARMA : Q1 21 – a mixed bag Alphavalue
FAES FARMA : Bilastine weighed on FY20; capacity expansion to cater underlying demand Alphavalue
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
3.65 EUR
Average target price
3.7 EUR
Spread / Average Target
+1.37%
High Price Target
4.3 EUR
Spread / Highest target
+17.81%
Low Price Target
3.2 EUR
Spread / Lowest Target
-12.33%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Faes Farma, S.A.

alphavalue Abhishek Raval

Ratings for Faes Farma, S.A.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. FAE Stock
  4. Consensus Faes Farma, S.A.